Erhardt Joseph A, Erickson-Miller Connie L, Aivado Manuel, Abboud Melanie, Pillarisetti Kodandaram, Toomey John R
Department of Oncology, GlaxoSmithKline, Collegeville, PA 19426, USA.
Exp Hematol. 2009 Sep;37(9):1030-7. doi: 10.1016/j.exphem.2009.06.011. Epub 2009 Jul 24.
The thrombopoietin receptor (TPOR) is a therapeutic target for treatment of thrombocytopenia because stimulation of this receptor results in enhanced megakaryocyte proliferation, differentiation, and ultimately platelet production. In addition to effects on megakaryocytes, TPOR stimulation also impacts platelet function. The present study examined platelet function following stimulation with the small molecule TPOR agonist eltrombopag.
Platelets were obtained from healthy volunteers, and signal transduction pathway activation was examined in washed platelet preparations. Platelet aggregation was examined in both washed platelet preparations and platelet-rich plasma. Platelet alpha-granule release was determined via fluorescein-activated cell sorting measurement of CD62P.
In signal transduction studies of washed human platelets, eltrombopag induced the phosphorylation signal transducers and activators of transcription (STAT) proteins with no phosphorylation of Akt, whereas recombinant human TPO (rhTPO) induced the phosphorylation of Akt as well as STAT-1, -3, and -5. In studies conducted at subthreshold/submaximal concentrations of adenosine diphosphate (ADP) or collagen, eltrombopag pretreatment did not result in platelet aggregation. In contrast, rhTPO acted in synergy with submaximal concentrations of ADP or collagen to induce maximal aggregation under all conditions examined. Similarly, platelet activation as examined via surface expression of CD62P was not enhanced by eltrombopag pretreatment as compared to rhTPO.
These results demonstrate that the nonpeptidyl TPOR agonist eltrombopag stimulates platelet signal transduction with little or no effect on overall platelet function, in contrast to TPO, which significantly primes platelet activation. These data demonstrate that effects of TPOR ligands on platelet function can vary depending on the specific mechanism utilized to stimulate the TPOR.
血小板生成素受体(TPOR)是治疗血小板减少症的一个治疗靶点,因为刺激该受体可增强巨核细胞的增殖、分化,并最终增加血小板生成。除了对巨核细胞有作用外,TPOR刺激还会影响血小板功能。本研究检测了小分子TPOR激动剂艾曲泊帕刺激后的血小板功能。
从健康志愿者获取血小板,并在洗涤后的血小板制剂中检测信号转导通路激活情况。在洗涤后的血小板制剂和富血小板血浆中检测血小板聚集情况。通过对CD62P进行荧光激活细胞分选测量来确定血小板α颗粒释放情况。
在洗涤后的人血小板信号转导研究中,艾曲泊帕诱导了信号转导及转录激活因子(STAT)蛋白的磷酸化,而Akt未发生磷酸化,而重组人血小板生成素(rhTPO)诱导了Akt以及STAT-1、-3和-5的磷酸化。在低于阈值/亚最大浓度的二磷酸腺苷(ADP)或胶原的研究中,艾曲泊帕预处理未导致血小板聚集。相比之下,在所有检测条件下,rhTPO与亚最大浓度的ADP或胶原协同作用以诱导最大聚集。同样,与rhTPO相比,艾曲泊帕预处理并未增强通过CD62P表面表达检测的血小板激活。
这些结果表明,与TPO显著引发血小板激活相反,非肽基TPOR激动剂艾曲泊帕刺激血小板信号转导,但对整体血小板功能几乎没有影响。这些数据表明,TPOR配体对血小板功能的影响可能因刺激TPOR所采用的具体机制而异。